QPD101

QPD101 is an investigational therapeutic candidate being developed by RestoriT, a biotechnology company focused on andrology and supportive care. As of early 2025, the asset is part of RestoriT's internal pipeline, specifically targeting applications within the field of men's health and supportive treatments. While the company has identified QPD101 for these indications, specific details regarding its molecular target, pharmacological modality (e.g., small molecule vs. biologic), and exact mechanism of action have not been publicly disclosed. The drug is currently in the early stages of development, aimed at addressing unmet needs in male reproductive health and related supportive care settings.